லெவின் புற்றுநோய் நிறுவனம் இல் சார்லோட் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from லெவின் புற்றுநோய் நிறுவனம் இல் சார்லோட். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In லெவின் புற்றுநோய் நிறுவனம் இல் சார்லோட் Today - Breaking & Trending Today

FDA approves new imaging tool to find advanced prostate cancer, drugmaker says


FDA approves new imaging tool to find advanced prostate cancer, drugmaker says
TODAY
2 hrs ago
© Provided by TODAY
The Food and Drug Administration has approved a new imaging agent to detect prostate cancer after it has spread to other parts of the body, the company that makes the agent said Thursday.
Experts say the tracer, made by medical imaging company Lantheus, will give doctors an important visual aid to guide them to metastatic prostate cancer cells that, before now, were difficult to spot.
Prostate cancer is the second leading cause of cancer deaths in men in the United States, after lung cancer, according to the American Cancer Society. More than 34,000 men die of the disease every year. ....

New York , United States , Memorial Sloan Kettering Cancer Center , North Carolina , Dana Farber Cancer Institute , San Francisco , Michael Morris , Los Angeles , Xiao Wei , Derek Raghavan , Thomas Hope , Justin Gregg , University Of California , Department Of Radiology , Drug Administration , Md Anderson Cancer Center , Levine Cancer Institute In Charlotte , American Cancer Society , American Cancer , Cancer Center , Levine Cancer Institute , புதியது யார்க் , ஒன்றுபட்டது மாநிலங்களில் , நினைவகம் ஸ்லோன் கெட்டரிங் புற்றுநோய் மையம் , வடக்கு கரோலினா , டானா ஃபார்‌பர் புற்றுநோய் நிறுவனம் ,

Clinical Challenges: CAR T-Cell Therapy in Multiple Myeloma


email article
The advent of next-generation proteasome inhibitors, immunomodulatory agents, and monoclonal antibodies over the last decade has revolutionized the way patients with multiple myeloma are managed.
However, the disease remains challenging, as relapse and disease progression remain common, even after complete remission. Myeloma often mutates and becomes more resistant to subsequent lines of therapy, leading to shorter responses and remissions.
Why CAR T-Cell Therapy?
Chimeric antigen receptor (CAR) T-cell therapy is one of the latest available therapeutic strategies in relapsed or refractory multiple myeloma (RRMM). Why is this a promising approach?
The bigger question is why CAR T-cell therapy is a good strategy for blood cancer to begin with, said Saad Usmani, MD, of the Levine Cancer Institute in Charlotte, North Carolina. ....

United States , University Of Texas Southwestern Medical Center , North Carolina , Larry Anderson Jr , Saad Usmani , American Society Of Hematology , Levine Cancer Institute In Charlotte , Levine Cancer Institute , Texas Southwestern Medical Center , Multiple Myeloma , Graft Versus Host Disease , Cytokine Release Syndrome , ஒன்றுபட்டது மாநிலங்களில் , பல்கலைக்கழகம் ஆஃப் டெக்சாஸ் தென்மேற்கு மருத்துவ மையம் , வடக்கு கரோலினா , ஸாட் உஸ்மானி , அமெரிக்கன் சமூகம் ஆஃப் ஹீமாட்டாலஜி , லெவின் புற்றுநோய் நிறுவனம் இல் சார்லோட் , லெவின் புற்றுநோய் நிறுவனம் , டெக்சாஸ் தென்மேற்கு மருத்துவ மையம் , பல மைலோமா , ஒட்டு எதிராக தொகுப்பாளர் நோய் ,